A Phase 3 interventional study of VGX-3100 and Matched Placebo in Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion and HSIL, sponsored by Inovio Pharmaceuticals. Completed at 53 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.
Sponsored by Inovio Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Uterine Cervical Dysplasia with a site in United States — 10 open to participants now, 14 under way, none of them phase 3. Uterine Cervical Dysplasia · United States.
Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, this one is the 25th largest by enrollment of the 86 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 88th registered.
409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.
Browse Uterine Cervical Dysplasia studies →10 of the 109 studies in Uterine Cervical Dysplasia with a site in United States are open now. Recruiting first, the newest first:
PapiVax Biotech, Inc. · Sites in United States, Taiwan
Ages 18–60 · Women only
Lindsay Ferguson, MD · Sites in United States
Ages 18+ · Women only
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
Northwell Health · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 14 · Phase 4 2
First in 1993; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 203 is above the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.
Median enrollment 80 across the 86 interventional studies, 250 across the 21 observational. Of the 83 that completed or were terminated, 27 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 109 have an industry lead sponsor. The 10 most frequent:
Inovio Pharmaceuticals is the lead sponsor of 31 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 10 (71%) have results posted.
Inovio Pharmaceuticals has 3 studies filed under Uterine Cervical Dysplasia — fewer than ten, so there is no comparison to draw.
4 of the studies in Uterine Cervical Dysplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06191133Lindsay Ferguson, MDFenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | 2026-12-30 |
| NCT04712851Jonsson Comprehensive Cancer CenterPembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | 2027-01-31 |
| NCT05051722Mayo ClinicLeveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | 2027-07-30 |
| NCT07520188UNC Lineberger Comprehensive Cancer CenterC-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed high-grade squamous intraepithelial lesions (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) of the cervix, associated with human papillomavirus (HPV-16) and/or HPV-18.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 IM injections of 6 mg (in 1 mL) VGX-3100 followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
Biological: VGX-3100 · Device: CELLECTRA™-5PSP
Participants received 3 IM injections of 1 mL VGX-3100 matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
Biological: Matched Placebo · Device: CELLECTRA™-5PSP
1 milliliter (mL) VGX-3100 injected IM.
1 mL of matched Placebo injected IM.
CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples
Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
Baseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Local and Systemic Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site induration, injection site pain, injection site pruritus, injection site swelling, malaise, pyrexia, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for baseline biomarker-positive participants for safety population.
Time frame: From Baseline to Week 40
Safety Population: Number of Participants With Local and Systemic AEs
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, chills, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site haemorrhage, injection site induration, injection site oedema, injection site pain, injection site paraesthesia, injection site pruritus, injection site swelling, malaise, pain, pyrexia, temperature regulation disorder, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for safety population.
Time frame: From Baseline to Week 40
Baseline Biomarker-positive Participants for Safety Population: Number of Participants With Any Treatment Emergent AEs (TEAEs) and Serious TEAEs (Including Suspected Unexpected Serious Adverse Reaction [SUSAR] and Unexpected Adverse Device Effect [UADE])
AE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) is any experience that suggested significant hazard, contraindication, side effect/precaution, \& fulfilled any of the following: fatal, life-threatening, required in-patient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant/required intervention to prevent other outcomes. TEAEs are any AEs starting on or after the first administration of any investigational product (IP). TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.
Time frame: From Baseline to Week 40
Safety Population: Number of Participants With Any TEAEs and Serious TEAEs (Including SUSAR and UADE)
AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. SAE is any experience that suggested significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent other outcomes. TEAEs are defined as AEs starting on or after the first administration of any IP. TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.
Time frame: From Baseline to Week 40
ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample
Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing
Baseline biomarker-positive participants with no evidence of HPV-16 and/or HPV-18 at Week 36 time frame and participants in whom an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing
Participants with no evidence of HPV-16 and/or HPV-18 at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of LSIL or HSIL on Histology Sample
Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
ITT Population: Percentage of Participants With No Evidence of Histologic LSIL or HSIL on Histology Sample
Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing
Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing
Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: At Week 36
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma
Baseline biomarker-positive participants with no histologic evidence of cervical adenocarcinoma in situ (AIS) or cervical carcinoma at Week 36 relative to baseline and participants in whom an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: From Baseline at Week 36
ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma
Participants with no histologic evidence of cervical AIS or cervical carcinoma at Week 36 relative to baseline and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
Time frame: From Baseline at Week 36
Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations
Percentage of baseline biomarker-positive participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina and intra-anal) at Week 36 Visit compared to baseline were reported.
Time frame: From Baseline at Week 36
ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations
Percentage of participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina, and intra-anal) at Week 36 Visit compared to baseline were reported.
Time frame: From Baseline at Week 36
Baseline Biomarker-positive Participants for mITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody
A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.
Time frame: At Week 15 and Week 36
mITT Population: Serum Concentrations of Anti-HPV-16 and Anti-HPV-18 Antibody
A standardized binding ELISA was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.
Time frame: At Week 15 and Week 36
Baseline Biomarker-positive Participants for mITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36
Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.
Time frame: Baseline; Week 15 and Week 36
mITT Population: Change From Baseline in Interferon-Gamma Response Magnitude at Week 15 and 36
Assessment of cellular immune activity occurred via the application of the IFN-γ ELISpot. PBMCs isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.
Time frame: Baseline; Week 15 and Week 36
Baseline Biomarker-positive Participants for mITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15
Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.
Time frame: Baseline, Week 15
mITT Population: Change From Baseline in Flow Cytometry Response Magnitude at Week 15
Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.
Time frame: Baseline, Week 15
Participants took part in the study at 53 study sites from 28 February 2019 to 15 September 2022.
| Milestone | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Started | 134 | 69 |
| Intent-to-treat (itt) population | 134 | 69 |
| Baseline biomarker-positive participants for itt | 21 | 4 |
| Safety set | 134 | 68 |
| Modified itt (mitt) population | 130 | 68 |
| Completed | 121 | 64 |
| Not completed | 13 | 5 |
| Withdrew: Withdrawal by subject | 6 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Reason not specified | 0 | 2 |
Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples | 28.6 | 0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site induration, injection site pain, injection site pruritus, injection site swelling, malaise, pyrexia, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for baseline biomarker-positive participants for safety population.
| Participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Nausea | 6 | 0 |
| Fatigue | 10 | 2 |
| Injection Site Bruising | 7 | 1 |
| Injection Site Erythema | 4 | 2 |
| Injection Site Haematoma | 1 | 0 |
| Injection Site Induration | 1 | 0 |
| Injection Site Pain | 19 | 4 |
| Injection Site Pruritus | 7 | 2 |
| Injection Site Swelling | 10 | 2 |
| Malaise | 2 | 1 |
| Pyrexia | 4 | 0 |
| Arthralgia | 6 | 0 |
| Myalgia | 13 | 2 |
| Headache | 13 | 3 |
| Erythema | 1 | 0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as AEs. Nausea, chills, fatigue, injection site bruising, injection site erythema, injection site haematoma, injection site haemorrhage, injection site induration, injection site oedema, injection site pain, injection site paraesthesia, injection site pruritus, injection site swelling, malaise, pain, pyrexia, temperature regulation disorder, arthralgia, myalgia, headache and erythema were considered as local and systemic AEs for safety population.
| Participants | VGX-3100 + EP | Matched Placebo + EP | Mixed Treatment |
|---|---|---|---|
| Nausea | 36 | 17 | 0 |
| Chills | 2 | 1 | 0 |
| Fatigue | 56 | 33 | 1 |
| Injection Site Bruising | 21 | 11 | 0 |
| Injection Site Erythema | 36 | 15 | 0 |
| Injection Site Haematoma | 10 | 7 | 0 |
| Injection Site Haemorrhage | 1 | 0 | 0 |
| Injection Site Induration | 3 | 0 | 0 |
| Injection Site Oedema | 5 | 2 | 0 |
| Injection Site Pain | 123 | 58 | 1 |
| Injection Site Paraesthesia | 1 | 0 | 0 |
| Injection Site Pruritus | 33 | 22 | 0 |
| Injection Site Swelling | 43 | 19 | 0 |
| Malaise | 18 | 12 | 1 |
| Pain | 1 | 1 | 0 |
| Pyrexia | 11 | 5 | 0 |
| Temperature Regulation Disorder | 1 | 0 | 0 |
| Arthralgia | 29 | 14 | 0 |
| Myalgia | 56 | 29 | 0 |
| Headache | 66 | 37 | 0 |
| Erythema | 1 | 0 | 0 |
AE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. Serious AE (SAE) is any experience that suggested significant hazard, contraindication, side effect/precaution, \& fulfilled any of the following: fatal, life-threatening, required in-patient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant/required intervention to prevent other outcomes. TEAEs are any AEs starting on or after the first administration of any investigational product (IP). TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.
| Participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Participants with any TEAEs | 20 | 4 |
| Participants with any Serious TEAEs | 3 | 0 |
| Participants with SUSAR | 0 | 0 |
| Participants with UADE | 0 | 0 |
AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. SAE is any experience that suggested significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent other outcomes. TEAEs are defined as AEs starting on or after the first administration of any IP. TEAEs included both serious and non-serious TEAEs. UADE is any SAE on health/safety or any life-threatening problem/death caused by, or associated with a device, if that effect, problem/death was not previously identified in nature, severity/degree of incidence in the investigational plan or application.
| Participants | VGX-3100 + EP | Matched Placebo + EP | Mixed Treatment |
|---|---|---|---|
| Participants with any TEAEs | 131 | 67 | 1 |
| Participants with any Serious TEAEs | 9 | 9 | 0 |
| Participants with SUSAR | 0 | 0 | 0 |
| Participants with UADE | 0 | 0 | 0 |
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples | 27.6 | 8.7 |
Baseline biomarker-positive participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample | 38.1 | 25.0 |
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample | 34.3 | 21.7 |
Baseline biomarker-positive participants with no evidence of HPV-16 and/or HPV-18 at Week 36 time frame and participants in whom an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing | 38.1 | 0 |
Participants with no evidence of HPV-16 and/or HPV-18 at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep™. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| ITT Population: Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing | 38.1 | 10.1 |
Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of LSIL or HSIL on Histology Sample | 38.1 | 25.0 |
Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at Week 36 and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| ITT Population: Percentage of Participants With No Evidence of Histologic LSIL or HSIL on Histology Sample | 32.1 | 14.5 |
Baseline biomarker-positive participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing | 28.6 | 0 |
Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at Week 36, and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. No evidence of LSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| ITT Population: Percentage of Participants With No Evidence of LSIL or HSIL on Histology Sample and No Evidence of HPV-16 and/or HPV-18 by Type Specific HPV Testing | 26.1 | 5.8 |
Baseline biomarker-positive participants with no histologic evidence of cervical adenocarcinoma in situ (AIS) or cervical carcinoma at Week 36 relative to baseline and participants in whom an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma | 76.2 | 75.0 |
Participants with no histologic evidence of cervical AIS or cervical carcinoma at Week 36 relative to baseline and participants who did not have unscheduled excision or biopsy sample obtained between the initial dose up to Week 36 were considered to be responders. The efficacy time frame is defined by a biopsy or surgical excision at any time starting from 14 days prior to the protocol-specified target date of Week 36. The first tissue removal sample within the time frame determines the histology endpoint.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| ITT Population: Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma | 82.1 | 76.8 |
Percentage of baseline biomarker-positive participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina and intra-anal) at Week 36 Visit compared to baseline were reported.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations | 19.0 | 25.0 |
Percentage of participants who have cleared HPV-16 and/or HPV-18 on specimens from non-cervical anatomic locations (oropharynx, vagina, and intra-anal) at Week 36 Visit compared to baseline were reported.
| percentage of participants | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| ITT Population: Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations | 22.4 | 10.1 |
A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.
| reciprocal endpoint titer | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| HPV-16 E7 at Week 15 | 450.0 (1 to 18225) | 1.0 (1 to 1) |
| HPV-16 E7 at Week 36 | 13.0 (1 to 18225) | 1.0 (1 to 18225) |
| HPV-18 E7 at Week 15 | 4050.0 (1 to 18225) | 1.0 (1 to 1) |
| HPV-18 E7 at Week 36 | 675.0 (1 to 18225) | 1.0 (1 to 18225) |
A standardized binding ELISA was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100. E7 is a viral protein produced by cells infected by HPV-16/18.
| reciprocal endpoint titer | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| HPV-16 E7 at Week 15 | 225.0 (1 to 18225) | 1.0 (1 to 75) |
| HPV-16 E7 at Week 36 | 1.0 (1 to 18225) | 1.0 (1 to 18225) |
| HPV-18 E7 at Week 15 | 2025.0 (1 to 18225) | 1.0 (1 to 18225) |
| HPV-18 E7 at Week 36 | 675.0 (1 to 18225) | 1.0 (1 to 18225) |
Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.
| spot forming units (SFU)/10^6 PBMC | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| HPV-16 E6: Baseline | 1.67 (0.0 to 11.7) | 4.17 (0.0 to 8.3) |
| HPV-16 E6: Change from Baseline at Week 15 | 25.00 (0.0 to 73.3) | 0.00 (0.0 to 0.0) |
| HPV-16 E6: Change from Baseline at Week 36 | 15.00 (0.0 to 38.3) | 0.0 (0.0 to 0.0) |
| HPV-16 E7: Baseline | 0.00 (0.0 to 5.0) | 1.67 (0.0 to 3.3) |
| HPV-16 E7: Change from Baseline at Week 15 | 16.67 (0.0 to 85.0) | 0.00 (0.0 to 0.0) |
| HPV-16 E7: Change from Baseline at Week 36 | 5.00 (0.0 to 36.7) | 0.00 (0.0 to 0.0) |
| HPV-18 E6: Baseline | 0.00 (0.0 to 11.7) | 2.50 (0.0 to 5.0) |
| HPV-18 E6: Change from Baseline at Week 15 | 26.67 (0.0 to 181.7) | 0.00 (0.0 to 0.0) |
| HPV-18 E6: Change from Baseline at Week 36 | 11.67 (0.0 to 31.7) | 0.00 (0.0 to 0.0) |
| HPV-18 E7: Baseline | 0.00 (0.0 to 3.3) | 4.17 (0.0 to 8.3) |
| HPV-18 E7: Change from Baseline at Week 15 | 3.33 (0.0 to 46.7) | 0.00 (0.0 to 0.0) |
| HPV-18 E7: Change from Baseline at Week 36 | 4.17 (0.0 to 20.0) | 0.00 (0.0 to 0.0) |
Assessment of cellular immune activity occurred via the application of the IFN-γ ELISpot. PBMCs isolated from whole blood sample were used for analysis. E6 and E7 are viral proteins produced by cells infected by HPV-16/18.
| SFU/10^6 PBMC | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| HPV-16 E6: Baseline | 1.67 (0.0 to 25.0) | 0.00 (0.0 to 15.8) |
| HPV-16 E6: Change from Baseline at Week 15 | 10.00 (0.0 to 115.0) | 1.67 (0.0 to 16.7) |
| HPV-16 E6: Change from Baseline at Week 36 | 8.33 (0.0 to 110.0) | 0.00 (0.0 to 23.3) |
| HPV-16 E7: Baseline | 0.00 (0.0 to 11.7) | 0.00 (0.0 to 15.0) |
| HPV-16 E7: Change from Baseline at Week 15 | 6.67 (0.0 to 236.7) | 0.00 (0.0 to 21.7) |
| HPV-16 E7: Change from Baseline at Week 36 | 3.33 (0.0 to 101.7) | 0.00 (0.0 to 8.3) |
| HPV-18 E6: Baseline | 0.00 (0.0 to 11.7) | 0.00 (0.0 to 11.7) |
| HPV-18 E6: Change from Baseline at Week 15 | 26.67 (0.0 to 885.0) | 0.00 (0.0 to 68.3) |
| HPV-18 E6: Change from Baseline at Week 36 | 19.17 (0.0 to 510.0) | 0.00 (0.0 to 35.0) |
| HPV-18 E7: Baseline | 0.00 (0.0 to 13.3) | 0.00 (0.0 to 18.3) |
| HPV-18 E7: Change from Baseline at Week 15 | 5.83 (0.0 to 291.7) | 0.00 (0.0 to 15.0) |
| HPV-18 E7: Change from Baseline at Week 36 | 3.33 (0.0 to 246.7) | 0.00 (0.0 to 135.0) |
Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.
| percentage of cells | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| CD8+CD137+Perforin+: Baseline | 0.000 (0.00 to 0.16) | 0.020 (0.00 to 0.04) |
| CD8+CD137+Perforin+: Change from Baseline at Week 15 | 0.035 (0.00 to 0.33) | 0.002 (0.00 to 0.002) |
| CD8+CD38+Perforin+: Baseline | 0.000 (0.00 to 0.04) | 0.027 (0.00 to 0.05) |
| CD8+CD38+Perforin+: Change from Baseline at Week 15 | 0.005 (0.00 to 0.21) | 0.000 (0.00 to 0.00) |
| CD8+CD69+Perforin+: Baseline | 0.008 (0.00 to 0.05) | 0.003 (0.00 to 0.01) |
| CD8+CD69+Perforin+: Change from Baseline at Week 15 | 0.042 (0.00 to 0.31) | 0.030 (0.00 to 0.05) |
Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38, and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here, changes from baseline in the percentage of CD8+CD137+Perforin+, CD8+CD38+Perforin+, and CD8+CD69+Perforin+ are reported.
| percentage of cells | VGX-3100 + EP | Matched Placebo + EP |
|---|---|---|
| CD8+CD137+Perforin+: Baseline | 0.000 (0.00 to 0.29) | 0.012 (0.00 to 0.24) |
| CD8+CD137+Perforin+: Change from Baseline at Week 15 | 0.049 (0.00 to 0.33) | 0.000 (0.00 to 0.10) |
| CD8+CD38+Perforin+: Baseline | 0.001 (0.00 to 0.09) | 0.007 (0.00 to 0.09) |
| CD8+CD38+Perforin+: Change from Baseline at Week 15 | 0.023 (0.00 to 0.27) | 0.000 (0.00 to 0.07) |
| CD8+CD69+Perforin+: Baseline | 0.003 (0.00 to 0.14) | 0.007 (0.00 to 0.09) |
| CD8+CD69+Perforin+: Change from Baseline at Week 15 | 0.037 (0.00 to 0.31) | 0.000 (0.00 to 0.06) |
Collected over From Baseline to Week 40. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VGX-3100 + EP | 0/134 (0%) | 9/134 (6.7%) | 131/134 (97.8%) |
| Matched Placebo + EP | 0/67 (0%) | 9/67 (13.4%) | 67/67 (100%) |
| Mixed Treatment | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | VGX-3100 + EP | Matched Placebo + EP | Mixed Treatment |
|---|---|---|---|
| Cervix carcinoma stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/134 | 3/67 | 0/1 |
| Squamous cell carcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/134 | 2/67 | 0/1 |
| Adenocarcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/134 | 1/67 | 0/1 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/134 | 1/67 | 0/1 |
| Ovarian ruptureReproductive system and breast disorders | 0/134 | 1/67 | 0/1 |
| AppendicitisInfections and infestations | 0/134 | 1/67 | 0/1 |
| COVID-19Infections and infestations | 1/134 | 0/67 | 0/1 |
| Event | VGX-3100 + EP | Matched Placebo + EP | Mixed Treatment |
|---|---|---|---|
| Injection site painGeneral disorders | 123/134 | 58/67 | 1/1 |
| FatigueGeneral disorders | 56/134 | 33/67 | 1/1 |
| MalaiseGeneral disorders | 18/134 | 12/67 | 1/1 |
| HeadacheNervous system disorders | 66/134 | 37/67 | 0/1 |
| MyalgiaMusculoskeletal and connective tissue disorders | 56/134 | 29/67 | 0/1 |
| Injection site pruritusGeneral disorders | 33/134 | 22/67 | 0/1 |
| Injection site swellingGeneral disorders | 43/134 | 19/67 | 0/1 |
| Injection site erythemaGeneral disorders | 36/134 | 15/67 | 0/1 |
| NauseaGastrointestinal disorders | 36/134 | 17/67 | 0/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 29/134 | 14/67 | 0/1 |
ITT population included all participants who were randomized.
| Age, Continuous(years) | VGX-3100 + EP | Matched Placebo + EP | Total |
|---|---|---|---|
| Mean | 31.6 ± 6.98 | 31.1 ± 7.93 | 31.4 ± 7.30 |
| Sex: Female, Male(Participants) | VGX-3100 + EP | Matched Placebo + EP | Total |
|---|---|---|---|
| Female | 134 | 69 | 203 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | VGX-3100 + EP | Matched Placebo + EP | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 16 | 41 |
| Not Hispanic or Latino | 108 | 53 | 161 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | VGX-3100 + EP | Matched Placebo + EP | Total |
|---|---|---|---|
| Asian | 3 | 0 | 3 |
| Black or African American | 8 | 2 | 10 |
| White | 116 | 66 | 182 |
| Other | 2 | 0 | 2 |
| Multiple | 5 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Aug 2022, 41 months.
Results were first posted in Oct 2024, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VGX-3100